Skip to main content

Table 1 Characteristics of the study patients

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Characteristics (total patients = 89)

 

Female, n (%)

78 (87.6)

Age, mean ± SD

46.8 ± 11.2

Years of migraine history, mean ± SD

28.2 ± 13.3

Baseline MMDs, mean ± SD

19.8 ± 8.4

Baseline analgesic days, mean ± SD

13.5 ± 10.6

Baseline triptan days, mean ± SD

8.7 ± 10.4

Chronic migraine, n (%)

84 (94.4)

Aura, n (%)

27 (30.3)

Allodynia, n (%)

33 (37.1)

Medication overuse, n (%)

64 (71.9)

Previous preventive treatment failures, n (%)

 2

28 (31.5)

 3

24 (27.0)

 4

26 (29.2)

 > 4

11 (12.4)

Botulinum toxin failure, n (%)

44 (49.4)

Concurrent oral preventive treatments at baseline, n (%)

37 (41.6)